151 filings
Page 5 of 8
6-K/A
y7d0jezubxux5zm
29 Jan 19
Current report (foreign) (amended)
4:31pm
6-K
jpfsep
29 Jan 19
ProQR Announces “ProQR Vision 2023” Strategy at its Annual R&D Day
8:47am
6-K
7he4lmk3o0n8zhdih4aj
7 Jan 19
ProQR Reaches Agreement with the FDA on Design of Phase 2/3 Pivotal Trial for Sepofarsen (QR-110) for Leber’s Congenital Amaurosis 10
7:05am
6-K
xracrtmdcnr9ux
13 Dec 18
ProQR Announces Strategic Changes to the Management Team and Key New Hires
7:30am
6-K
oisyccz ku
10 Dec 18
ProQR Receives € 4.7 million in Innovation Credit from Dutch Government for QR-110 for LCA10
4:18pm
6-K
8uhpiz12n2pjdrr7 mbe
4 Dec 18
ProQR Announces Clearance of IND to Start Clinical Trial of QR-421a in Usher Syndrome Type 2 Patients
8:38am
6-K
blzp02fdqc 5d5qh6ba
7 Nov 18
PROQR THERAPEUTICS N.V. Index to Unaudited Condensed Consolidated Financial Statements
4:40pm
6-K
iixcgu7oyi2lzlj
29 Oct 18
Current report (foreign)
4:30pm
6-K
db8mb3g
7 Sep 18
ProQR Prices $90.6 Million Underwritten Public Offering of Ordinary Shares
12:00am
6-K
2qca496po m2yp
5 Sep 18
ProQR Announces Positive Interim Results from Phase 1/2 Clinical Trial of QR-110 in LCA10 Patients, and Plans to Start a Phase 2/3 Pivotal Trial
12:00am
6-K
wio3xi3jnhl94vkk5yfd
5 Sep 18
ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares
12:00am
6-K
47q7i
8 Aug 18
PROQR THERAPEUTICS N.V. Index to Unaudited Condensed Consolidated Financial Statements
4:37pm
6-K
3j9m3 ch848tnqfy
29 Jun 18
ProQR Initiates Phase 1/2 Clinical Trial of QR-313 for Dystrophic Epidermolysis Bullosa
8:10am
6-K
a4y67p0ugzf 7dlnpi
12 Jun 18
The funding will be used for the clinical development of QR-313
12:00am
6-K
kuhq j62o
16 May 18
Current report (foreign)
4:30pm
6-K
smytxq
10 May 18
PROQR THERAPEUTICS N.V. Unaudited Condensed Consolidated Statement of Financial Position
6:55am
6-K
q6t71w
23 Apr 18
ProQR Provides Enrollment Update on QR-110 Clinical Trial and Highlights Ophthalmology Presentations at ARVO
12:00am
6-K
e96x 78k4fhtusfv
11 Apr 18
ProQR Announces Annual Meeting of Shareholders
12:00am
6-K
5tqo a5oe5c6e0f2
28 Feb 18
Index to Unaudited Condensed Consolidated Financial Statements
12:00am
6-K
n5qiea4fos l6e0ctm29
20 Feb 18
Current report (foreign)
12:00am